Expected consequences of moving US pharma manufacturing to the US
This statistic shows the results of a survey conducted in the United States in February 2017. U.S. adults were given a list of 11 options and asked to select which consequences they would expect if U.S. pharma companies were forced to move their manufacturing from abroad back to the U.S. About 42 percent of respondents said that they believe higher drug prices would be an expected consequence, while 10 percent of respondents thought that a decrease in manufacturing companies would be a consequence.